Plenary Speakers

• Plenary Lecture 1 Biomechanical perspectives and understandings of osteoporosis
  Day 2 (June 4, Fri), 11:30 - 12:20, Ch 1 Mary Bouxsein (Harvard University, USA)
  CV
  
• Plenary Lecture 2 Molecular players in Muscle-Bone cross talk: Role of Mitochondria and TGFbeta signaling
  Day 2 (June 4, Fri), 14:50 - 15:40, Ch 1 Marco Sandri (University of Padova, Italy)
  CV
  
• Plenary Lecture 3 Fat talks to bone
  Day 3 (June 5, Sat), 11:50 - 12:40, Ch 1 Steven Teitelbaum (Washington University, USA)
  CV
  
• Plenary Lecture 4 Combating the high risk of atypical femur fracture risk in Asian vs. Caucasian women: Developing a personalized medicine approach to osteoporosis treatment.
  Day 3 (June 5, Sat), 14:40 - 15:30, Ch 1 Dennis Black (UCSF, USA)
  CV
  

KSBMR-ASBMR-JSBMR Joint Symposium

• KSBMR-ASBMR-JSBMR Joint Symposium [Basic] In vivo mapping of subcellular proteomes in aging and disease
  Day 2 (June 4, Fri), 13:10-13:40, Ch 1 Jae Myoung Suh (KAIST, Korea (KSBMR))
  CV
  
• KSBMR-ASBMR-JSBMR Joint Symposium [Basic] The Kynurenine Pathway in Muscle Aging
  Day 2 (June 4, Fri), 13:40 - 14:10, Ch 1 Mark W. Hamrick (Augusta University, Medical College of Georgia, USA (ASBMR))
  CV
  
• KSBMR-ASBMR-JSBMR Joint Symposium [Basic] Muscle to tendon for physical performance
  Day 2 (June 4, Fri), 14:10 - 14:40, Ch 1 Hiroshi Asahara (Tokyo Medical and Dental University, Japan (JSBMR))
  CV
  

Symposium

• Symposium 1 [Clinical] Management of
  osteporosis in premenopausal women and young men Holistic view on Osteoporosis in Men
  Day 2 (June 4, Fri), 10:50 - 11:15, Ch 1 Eric Orwoll (Oregon Health & Science University, USA)
  CV
  
• Symposium 5 [Clinical] Recent development of biomarkers Biomarkers of Cellular Senescence
  Day 3 (June 5, Sat), 10:20 - 10:45, Ch 1 Nathan K LeBrasseur (Mayo clinic, USA)
  CV
  
• Symposium 5 [Clinical] Recent development of biomarkers D3Cr muscle mass: a new approach
  Day 3 (June 5, Sat), 10:45 - 11:10, Ch 1 Peggy Cawthon (UCSF, USA)
  CV
  
• Symposium 6 [Basic] Rare bone disease (FOP) How inhibition of Activin A became a therapeutic target for FOP
  Day 3 (June 5, Sat), 10:45-11:10, Ch 2 Aris Economides (Regeneron Pharma, Vice President for Research, USA)
  CV
  
• Symposium 6 [Basic] Rare bone disease (FOP) Evolving mechanisms of osteoimmunology in fibrodysplasia ossificans progressiva
  Day 3 (June 5, Sat), 11:10-11:35, Ch 2 Daniel Perrien (Emory University, USA)
  CV
  
• Symposium 2 [Basic] - Energy Metabolism and Bone Quality control of mitochondria: protection against osteoporosis
  Day 2 (June 4, Fri), 10:00-10:25, Ch 2 Ha-Neui Kim (University of Arkansas for Medical Sciences, USA)
  CV
  
• Symposium 8 [Basic] - Reverse Muscle Aging Dynamic regulation of mitochondrial metabolism in metabolic disease
  Day 3 (June 5(Sat), 2021, 15:45-16:10, Ch 2 Haejin Yoon (Harvard Medical School, USA)
  CV
  
• Symposium 4 [Basic] - Pathogenesis of Cartilage Disease IL-17 and immunologically induced senescence regulate response to injury in osteoarthritis
  Day 2 (June 4, Fri), 16:20-16:45, Ch 2 Jin Han (Johns Hopkins University School of Medicine, USA)
  CV
  

Working Group

• Working Group 3. CKD-MBD Working Group - Bone-Vascular Axis in CKD A focus on osteocyte cell signaling
  Day 1(June 3(Thu), 2021), 17:20-17:40, Ch 2 Amy Yoshiko Sato (University of Arkansas for Medical Sciences, USA)
  CV
  
• Working Group 5. Fracture Liaison Services Working Group - How to Change & Manage FLS Implementation in COVID-19 Era Secondary fracture prevention during the COVID-19 pandemic: Keeping the fire burning!
  Day 2(June 4(Fri), 2021), 13:10-13:30, Ch 2 Irewin A. Tabu (University of the Philippines Manila, Philippines)
  CV
  
• Working Group 5. Fracture Liaison Services Working Group - How to Change & Manage FLS Implementation in COVID-19 Era How to change & manage FLS implementation in COVID-19 era
  Day 2(June 4(Fri), 2021), 13:30-13:50, Ch 2 M Kassim Javaid (University of Oxford, UK)
  CV
  
• Working Group 6. Muscle Working Group - Capture the Sarcopenia: Mechanism-based and Evidence-based Approach Evidence-based clinical approach for sarcopenia
  Day 2(June 4(Fri), 2021), 15:20-15:50, Ch 2 Hidenori Arai (National Center for Geriatrics and Gerontology, Japan)
  CV
  
• Working Group 8. Parathyroid Working Group Congenital hypoparathyroidism associated with elevated circulating nonfunctional parathyroid hormone due to novel PTH mutation
  Day 3(June 5(Sat), 2021), 14:40-15:00, Ch 2 Matti Lauren Gild (Royal North Shore Hospital, Australia)
  CV
  
• Working Group 8. Parathyroid Working Group Complications of chronic hypoparathyroidism
  Day 3(June 5(Sat), 2021), 15:00-15:20, Ch 2 Tay Yu Kwang Donovan (Sengkang General Hospital, Singhealth, Duke NUS Medical School, Singapore)
  CV
  
• Working Group 2. Exercise, Nutrition Working Group - Current Concepts in the Exercise & Nutrition for Bone Health Aerobic exercise and peripheral nerve in bone
  Day 1(June 3(Thu), 2021), 16:50-17:10, Ch 2 Seungyong Lee (Midwestern University at Glendale, USA)
  CV
  
• Working Group 2. Exercise, Nutrition Working Group - Current Concepts in the Exercise & Nutrition for Bone Health Different types of mechanical loading and three-dimensional trabecular bone microarchitecture in rat
  Day 1(June 3(Thu), 2021), 16:30-16:50, Ch 2 Yong-In Ju (Kawasaki University of Medical Welfare, Japan)
  CV